Last reviewed · How we verify
Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (STAR-02)
To evaluate the initial efficacy and safety of neoadjuvant low-dose interval radiotherapy combined with tirelizumab and SOX chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma.
Details
| Lead sponsor | Shandong Provincial Hospital |
|---|---|
| Phase | PHASE2 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 32 |
| Start date | Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Dec 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Interventions
- Neoadjuvant Therapy(5×3Gy radiotherapy)
- Neoadjuvant Therapy(tirelizumab, oxaliplatin, S-1)
- Surgical treatment
- Adjuvant therapy(SOX chemotherapy)